EGFR and gastric carcinoma: The adaptive activation of the EGFR axis in gastric carcinoma cells after HDACi treatment shown in our study not only represents an important resistance factor to HDACi, but also opens up the possibility of combination therapy with EGFR inhibitors in the sense of acquired vulnerability.